Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association
Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, Kris-Etherton PM, Jacobson TA, Engler MB, Alger HM, Appel LJ, Mozaffarian D, American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology
Circulation · 455 citas
Cómo se estudió
- Diseño
- Ficha de expertos o del gobierno (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Heart, Lung, and Blood Institute
- Gobierno
- NHLBI NIH HHS
- Subvenciones
- National Heart, Lung, and Blood Institute (R01 HL085710); National Heart, Lung, and Blood Institute (R01 HL101236)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2017-03-13 · Circulation · vol. 135 · número 15 · págs. e867–e884
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 633 citas · más que el 100% de estudios similares · 51.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 52 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Fatty Acid Research and Health · Diet and metabolism studies · Diet, Metabolism, and Disease
- Palabras clave
- Medicine, Eicosapentaenoic acid, Docosahexaenoic acid, Prediabetes, Diabetes mellitus, Polyunsaturated fatty acid, Population, Internal medicine, Clinical trial, Fish oil, Disease, Randomized controlled trial, Intensive care medicine, Type 2 diabetes, Fatty acid, Endocrinology, Environmental health
- MeSH
- humans, cardiovascular diseases, atrial fibrillation, diabetes mellitus, diabetes complications, fatty acids, omega-3, fish oils, cardiac surgical procedures, risk, primary prevention, dietary supplements, heart failure, stroke, secondary prevention
12 autores
- David S. Siscovick
- T. A. Barringer🇺🇸Schrodinger (United States)
- Amanda M. Fretts
- Jason H. Y. Wu
- Alice Hinda Lichtenstein🇩🇪Alice-Salomon-Hochschule Berlin
- Rebecca B. Costello
- Penny M. Kris‐Etherton🇺🇸Penny George Institute for Health and Healing
- Terry A. Jacobson🇺🇸Jacobs (United States)
- Mary B. Engler
- Heather M. Alger
- Lawrence J. Appel
- Dariush Mozaffarian
Resumen
El texto original del estudio, en el idioma en que se publicó.
Multiple randomized controlled trials (RCTs) have assessed the effects of supplementation with eicosapentaenoic acid plus docosahexaenoic acid (omega-3 polyunsaturated fatty acids, commonly called fish oils) on the occurrence of clinical cardiovascular diseases. Although the effects of supplementation for the primary prevention of clinical cardiovascular events in the general population have not been examined, RCTs have assessed the role of supplementation in secondary prevention among patients with diabetes mellitus and prediabetes, patients at high risk of cardiovascular disease, and those with prevalent coronary heart disease. In this scientific advisory, we take a clinical approach and focus on common indications for omega-3 polyunsaturated fatty acid supplements related to the prevention of clinical cardiovascular events. We limited the scope of our review to large RCTs of supplementation with major clinical cardiovascular disease end points; meta-analyses were considered secondarily. We discuss the features of available RCTs and provide the rationale for our recommendations. We then use existing American Heart Association criteria to assess the strength of the recommendation and the level of evidence. On the basis of our review of the cumulative evidence from RCTs designed to assess the effect of omega-3 polyunsaturated fatty acid supplementation on clinical cardiovascular events, we update prior recommendations for patients with prevalent coronary heart disease, and we offer recommendations, when data are available, for patients with other clinical indications, including patients with diabetes mellitus and prediabetes and those with high risk of cardiovascular disease, stroke, heart failure, and atrial fibrillation.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.